Acute phase response, cytokine cascade 1, 2
Allergic colitis, inflammatory bowel disease risk 119
5-Aminosalicylic acid, inflammatory bowel disease treatment 101, 147, 208, 237
Anemia, management with inflammatory bowel disease
cobalamin deficiency 164, 165
erthropoietin therapy 169
iron deficiency 162–164, 167–169
Anticipation, Crohn’s disease 24
Antioxidant defenses
glutamine supplementation effects 221–223
inflammation 66, 67, 217, 218
nutrition effects
  glutathione 68–70
  lipid intake 72–74, 78–81
  metallic micronutrients 67, 68, 77, 78
  miscellaneous antioxidants 67, 68
  protein and amino acid intake 68–71
  sites of activity 75, 76
  vitamin A 72
  vitamin C 71
  vitamin E 71, 78
Apoptosis
inhibition by glutamine during parenteral nutrition administration 219, 220
  regulation in intestinal epithelial cell 51, 53, 54, 59, 60
  ASCA test, distinguishing Crohn’s disease from ulcerative colitis 89, 117, 118, 120
  Azathioprine, inflammatory bowel disease treatment 139, 152, 237
  Bcl-2, apoptosis regulation in intestinal epithelial cells 54
  Biopsy, inflammatory lesions in gastrointestinal tract 95
  Bowel rest, see Total parenteral nutrition
  Budesonide, inflammatory bowel disease treatment 139, 152
  Butyrate
  effects on intestinal gene expression 135–137
  inflammation control 145
Candidate gene approach
association studies 26, 27
founder effect 28, 29
genes in inflammatory bowel disease 29, 30, 39
transmission disequilibrium test 27, 28
CD44 variant 6, expression in inflammatory bowel disease(s) 98
CDP571, inflammatory bowel disease treatment
  anti-antibody response 247
  cost 252
CDP571, inflammatory bowel disease treatment (continued)
  Crohn’s disease treatment 243
  features 241
  multiple infusions 244
  nutrition response 254, 255
  precautions
    cancer 249, 255
    children 249, 253, 254
    dosing 250
    drug absorption 249, 254
    extraintestinal manifestations 249
    immunosuppression 248
    infection 248
    infusion reactions 248
    long-acting effects 248, 249
    pregnancy 247, 248
  regulatory approval 253
  safety 246
  therapeutic subgroup identification 244, 245, 250
  ulcerative colitis treatment 245
Chemokines
  inflammatory bowel disease roles 48, 49
  lumen signaling to mucosal immune system 128, 129
Chromosome 12, susceptibility locus in inflammatory bowel disease 33, 34, 37, 38
Chromosome 16, susceptibility locus in inflammatory bowel disease 32, 34, 37, 38
Cobalamin deficiency, management with inflammatory bowel disease 164, 165
Colon cancer
  endoscopic surveillance 103, 115
  risk with ulcerative colitis 86, 102, 104
Colonoscopy, see Endoscopy
Corticosteroids, inflammatory bowel disease treatment 139, 175, 176, 178, 179, 184, 237
Crohn’s disease
  activity indexes 89, 101, 103, 183
  complications and management
    anemia
      cobalamin deficiency 164, 165
      erythropoietin therapy 169
      iron deficiency 162–164, 167–169
    osteoporosis 161, 162
  overview 88, 89

Cyclosporine, inflammatory bowel disease treatment 253
Diet
  gene expression regulation
  breast milk and gene expression in enterocytes 125, 126
  butyrate 135–137
intestinal atrophy reversal after total parental nutrition 157, 158
meta-analysis of studies 144, 174–177
pediatric treatment, see also CT3211 acceptance and compliance 180, 181, 187
corticosteroid efficacy comparison 175, 176, 178, 179, 183
cyclical nutrition 180
drug treatment factors 149
early recurrence of active disease 180
elemental vs non-elemental diets 179
formula composition and efficacy 178
mechanism of action 177, 178, 187, 188
meta-analysis of efficacy 174–177
site-specific efficacy 179, 180
supplemental nutrition 180
preoperative therapy 150
relapse 149
Epithelial cell, see Intestinal epithelial cell
Erythropoietin therapy, anemia 169
FAS, apoptosis regulation in intestinal epithelial cells 53, 54, 59
Fish oil
  anti-inflammatory activities 72–74,
  78–81, 199, 200, 209
  fish consumption effects on inflammatory bowel disease treatment 212, 213
supplementation in inflammatory bowel disease treatment
  clinical studies, history 201–203
  rationale 200
  relapse prevention 4, 43
  study of 45% EPA/20% DHA derivative
    absorption and tolerance 204, 205
    composition of supplement 203, 204, 211–215
    Crohn’s disease treatment 205–208
duration of treatment 212
gut resection patient treatment 208
study design 204
ulcerative colitis treatment 209
vitamin content 212, 213

Eicosapentaenoic acid, see Fish oil

Elimination diets, Crohn’s disease treatment 145, 147

Endoscopy
  colon cancer surveillance 103, 115
  inflammatory bowel disease diagnosis in children
    Crohn’s disease 108, 109
ulcerative colitis 114, 115
inflammatory lesion demonstration in gastrointestinal tract 95

Enteral nutrition, inflammatory bowel disease treatment
  adjunctive support vs primary treatment 174
disease remission compared to drug therapy 142–144, 146, 147
growth retardation in children
  mechanisms 172, 173
  prevalence in Crohn’s disease 171, 172
  reversal 145, 150
  gut-trophic growth factors 217

Erythropoietin therapy, anemia 169

FAS, apoptosis regulation in intestinal epithelial cells 53, 54, 59

Fish oil
  anti-inflammatory activities 72–74,
  78–81, 199, 200, 209
  fish consumption effects on inflammatory bowel disease treatment 212, 213
supplementation in inflammatory bowel disease treatment
  clinical studies, history 201–203
  rationale 200
  relapse prevention 4, 43
  study of 45% EPA/20% DHA derivative
    absorption and tolerance 204, 205
    composition of supplement 203, 204, 211–215
    Crohn’s disease treatment 205–208
  duration of treatment 212
gut resection patient treatment 208
study design 204
ulcerative colitis treatment 209
vitamin content 212, 213

Docosahexaenoic acid, see Fish oil

Eicosapentaenoic acid, see Fish oil

Elimination diets, Crohn’s disease treatment 145, 147

Endoscopy
  colon cancer surveillance 103, 115
  inflammatory bowel disease diagnosis in children
    Crohn’s disease 108, 109
ulcerative colitis 114, 115
inflammatory lesion demonstration in gastrointestinal tract 95

Enteral nutrition, inflammatory bowel disease treatment
  adjunctive support vs primary treatment 174
disease remission compared to drug therapy 142–144, 146, 147
growth retardation in children
  mechanisms 172, 173
  prevalence in Crohn’s disease 171, 172
  reversal 145, 150
  gut-trophic growth factors 217
Subject Index

Fistula, management with total parenteral nutrition 159, 167
Flavor packets, diet compliance effects 153
Interleukin-5, inflammatory bowel disease role 58
Interleukin-6
  acute phase response, cytokine cascade 1, 2
dietary fatty acid effects 72, 73
host defense 63, 64
inflammatory bowel disease role 45, 55
  suppression of insulin-like growth factor-I levels 173
Interleukin-7, inflammatory bowel disease role 55
Interleukin-8
  inflammatory bowel disease role 55
  intestinal lumen signaling to mucosal immune system 129
Interleukin-10, inflammatory bowel disease role 46, 61, 238
Interleukin-12, inflammatory bowel disease role 49, 238
Interleukin-13, inflammatory bowel disease role 46, 48
Intestinal epithelial cell 50
  apoptosis 51, 53, 54, 59, 60
cytokine production and inflammatory bowel disease role 55, 56
differentiation 51
gene expression regulation by nutrients
  breast milk and gene expression in enterocytes 125, 126
  butyrate 135–137
  enterocyte adaptation 123–125
  overview 122, 123
  polarity of nutrient-gene interactions in epithelia 123
  immune mediated alterations of turnover 50–54
  lumen signaling to mucosal immune system
    chemokine secretion 128, 129
class II major histocompatibility complex and invariant chain expression 129, 130, 132
insulin-like growth factor binding proteins 130, 131
  overview 127, 128
  therapeutic implications 131, 132
Intestinal flora, inflammatory bowel disease role 50, 186
Iron deficiency, management with inflammatory bowel disease 162–164, 167–169
Irritable bowel syndrome, diagnosis 94
Lactoferrin, breast milk ingestion effects on intestinal cell gene expression 125, 126
Linkage studies
ethnic groups 34, 38, 39
genome-wide scanning overview 30, 31, 38
  HLA-DRB1 locus 34
  limitations 31, 32
  susceptibility loci in inflammatory bowel disease 32–35
Macrophage inflammatory protein-2, intestinal lumen signaling to mucosal immune system 129
Major histocompatibility complex, class II molecule invariant chain expression, dietary effects 129, 130, 132
Malnutrition, see Protein-energy malnutrition
6-Mercaptopurine, inflammatory bowel disease treatment 139, 237
Mesalamine, inflammatory bowel disease treatment 139
Metronidazole, inflammatory bowel disease treatment 139
Microscopic colitides
  course in children 119
  features 81
  Monocyte chemoattractant protein-1, inflammatory bowel disease role 48, 49
Mycobacterium paratuberculosis, infection and inflammatory bowel disease risk 16, 44
NFκB
  human immunodeficiency virus replication response 64
  oxidative activation and stimulation of cytokine production 67, 78
Nonsteroidal anti-inflammatory drugs, colitis differential diagnosis from inflammatory bowel disease 96
Nutrition, see Diet
Oral contraceptives, inflammatory bowel disease risk factor 13
Subject Index

Osteoporosis, management with inflammatory bowel disease 161, 162
Pectin, supplementation of liquid diets 186
Perforation, risk with ulcerative colitis 86
Perinuclear antineutrophil cytoplasmic autoantibody, expression in inflammatory bowel disease(s) 99, 117, 118, 120
Physical inactivity, inflammatory bowel disease risk factor 14
Positron emission tomography, inflammatory bowel disease diagnosis in children 118
Pouchitis
activity index 90
features 91
Probiotics, inflammatory bowel disease treatment 186
Protein-energy malnutrition
causes in inflammatory bowel disease 140, 155, 156, 218
Crohn’s disease 3, 4, 156
cytokine induction in systemic inflammatory response 2, 3
ulcerative colitis 3, 4
Quality of life, scoring in inflammatory bowel disease treatment 150
Radiology, inflammatory lesions in gastrointestinal tract 95
RANTES, inflammatory bowel disease role 48, 49
Risk factors, inflammatory bowel disease
diet 13, 14, 18–21
eyearl life exposures 15, 16
familial history 23–25, 37, 42
infection 16, 19, 20, 43, 44
oral contraceptives 13
physical inactivity 14
socioeconomic status 14
stress 14, 15
tobacco use 11–13, 16
Salazopyrine, inflammatory bowel disease treatment 139
Smoking, see Tobacco
Socioeconomic status, inflammatory bowel disease risk factor 14
Stress, inflammatory bowel disease risk factor 14, 15
Sucrase, nutrient control of expression in enterocyte 124, 125
Systemic inflammatory response, diagnostic criteria 1
T cell
CD4+ cell activation in inflammatory bowel disease 56
CD4+ cell suppression with monoclonal antibodies 241
helper cell cytokines, roles in inflammatory bowel disease 49, 58
Tobacco, inflammatory bowel disease risk factor 11–13, 16
Total parenteral nutrition, inflammatory bowel disease treatment
Crohn’s disease 140, 141, 157
efficacy compared to other treatments 142, 146, 156, 157, 168
electrolyte replacement 170
gastrointestinal fistula management 159, 167
home administration in Crohn’s disease complications 159, 160, 169
outcomes 159, 160
preoperative therapy 151, 158
recommendations for use 165
ulcerative colitis 141, 142
Toxic megacolon, risk with ulcerative colitis 86
Transforming growth factor-β
CT3211 nutritional therapy, composition and response in children 191, 192, 194, 196–198
inflammatory bowel disease role 48, 238
Treatment, inflammatory bowel disease
5-aminosalicylic acid 101, 147, 208, 237
azathioprine 139, 152, 237
budesonide 139, 152
butyrate, inflammation control 145
complications and management
anemia
cobalamin deficiency 164, 165
erthropoietin therapy 169
iron deficiency 162–164, 167–169
osteoporosis 161, 162
overview 88, 89
corticosteroids 139, 175, 176, 178, 179, 184, 237
cyclosporine 253
elimination diets, Crohn’s disease treatment 145, 147
enteral nutrition
adjunctive support vs primary treatment 174
disease remission compared to drug therapy 142–144, 146, 147
gut-trophic growth factors 217
intestinal atrophy reversal after total parental nutrition 157, 158
meta-analysis of studies 144, 174–177
pediatric treatment, see also CT3211
acceptance and compliance 180, 181, 187
corticosteroid efficacy comparison 175, 176, 178, 179, 183
cyclical nutrition 180
drug treatment factors 149
early recurrence of active disease 180
elemental vs non-elemental diets 179
formula composition and efficacy 178
mechanism of action 177, 178, 187, 188
meta-analysis of efficacy 174–177
site-specific efficacy 179, 180
supplemental nutrition 180
preoperative therapy 150
relapse 149
fish oil supplementation
clinical studies, history 201–203
rationale 200
relapse prevention 4, 43
study of 45% EPA/20% DHA derivative
absorption and tolerance 204, 205
composition of supplement 203, 204, 211–215
Crohn’s disease treatment 205–208
duration of treatment 212
gut resection patient treatment 208
study design 204
ulcerative colitis treatment 209
flavor packets and diet compliance 153
glutamine supplementation
alternative compounds for administration 224, 232
antioxidant capacity effects 221–223
cell swelling hypothesis in mechanism 231
clinical trials and beneficial effects 224–227, 230
conditional essentiality 218, 219
experimental colitis models 223
experimental short bowel syndrome and jejunal transplantation 220
gut barrier function effects 221
gut trophic growth factor coadministration 233
immune response 226, 232
small peptide transport 224, 225, 234
stability of preparations 222, 224
tolerance 225, 227
total parenteral nutrition 157, 158, 232, 233
trophic effects during parenteral nutrition administration 219, 220
immunotherapy
CD4+ T cell suppression 241
goals 240
6-mercaptopurine 139, 237
mesalamine 139
metronidazole 139
overview 101
placebo effect 139
probiotics 186
quality of life scoring 150
relapse rates 152
salazopyrine 139
total parenteral nutrition and bowel rest
Crohn’s disease 140, 141, 157
efficacy compared to other treatments 142, 146, 156, 157, 168
electrolyte replacement 170
gastrointestinal fistula management 159, 167
home administration in Crohn’s disease complications 159, 160, 169
outcomes 159, 160
Subject Index

Treatment, inflammatory bowel disease
  total parenteral nutrition and bowel rest
  (continued)
    preoperative therapy 151, 158
    recommendations for use 165
  ulcerative colitis 141, 142
  tumor necrosis factor-α monoclonal
    antibody therapy
    CDP571
      anti-antibody response 247
      Crohn’s disease treatment 243
      features 241
      multiple infusions 244
      safety 246
      ulcerative colitis treatment 245
      cost 252
      humanization of antibodies 240
      infliximab
        anti-antibody response 246
        Crohn’s disease treatment 241–243
        features 241
        multiple infusions 243, 244
        safety 246
        ulcerative colitis treatment 245
        cost 252
        humanization of antibodies 240
        infliximab
          anti-antibody response 246
          Crohn’s disease treatment 241–243
          features 241
          multiple infusions 243, 244
          safety 246
          ulcerative colitis treatment 245
          nutrition response 254, 255
          precautions
            cancer 249, 255
            children 249, 253, 254
            dosing 250
            drug absorption 249, 254
            extraintestinal manifestations
            249
            immunosuppression 248
            infection 248
            infusion reactions 248
            long-acting effects 248, 249
            pregnancy 247, 248
            regulatory approval 253
            therapeutic subgroup identification
            244, 245, 250
    tuberculosis, differential diagnosis from
    inflammatory bowel disease 118
  Tumor necrosis factor-α
    acute phase response, cytokine cascade
    1, 2
    amino acid metabolism effects 69, 70
    anorexia induction 2, 153
    biological activities and elevation in
    disease 239
    dietary fatty acid effects 72, 73
    host defense 63, 64, 67
    inflammatory bowel disease role 45, 46, 52–55, 58–60, 238–240
    metabolic effects during infection and
    injury 65, 66
    monoclonal antibody therapy
    CDP571
      anti-antibody response 247
      Crohn’s disease treatment 243
      features 241
      multiple infusions 244
      safety 246
      ulcerative colitis treatment 245
      cost 252
      humanization of antibodies 240
      infliximab
        anti-antibody response 246
        Crohn’s disease treatment
        241–243
        features 241
        multiple infusions 243, 244
        safety 246
        ulcerative colitis treatment 245
        nutrition response 254, 255
        precautions
          cancer 249, 255
          children 249, 253, 254
          dosing 250
          drug absorption 249, 254
          extraintestinal manifestations
          249
          immunosuppression 248
          infection 248
          infusion reactions 248
          long-acting effects 248, 249
          pregnancy 247, 248
          regulatory approval 253
          therapeutic subgroup identification
          244, 245, 250
    Tumor necrosis factor-β, inflammatory
    bowel disease role 49
    Turner syndrome, inflammatory bowel
    disease association 39
    Twin studies, inflammatory bowel disease
    heredity 24, 37
  Ulcerative colitis
    complications
      colon cancer 86, 102, 104
      perforation 86
      toxic megacolon 86
    course 86, 87
    diagnosis
      children
        abdominal pain 117
        colonoscopy 114, 115
        histological diagnosis 110
        laboratory tests 113, 114, 117, 118, 120
        overview 113
      clinical trial criteria 99
      differential diagnosis
        infectious colitis 97
        overview 96
differentiation from Crohn’s disease 98, 99, 102, 104, 105
extradigestive symptoms 85, 86, 93, 94
inflammatory lesion demonstration in gastrointestinal tract 95
rectocolonic symptoms 84, 85, 93, 94
discovery 7
enteral nutrition in children 185
incidence studies, see Incidence studies, inflammatory bowel disease
pathology 83, 84
protein-energy malnutrition, overview 3, 4
rating scales of severity 83–85
risk factors, see Risk factors, inflammatory bowel disease
treatment, see Treatment, inflammatory bowel disease
Ultrasound, inflammatory lesions in gastrointestinal tract 95
Vitamin A, intake and anti-inflammatory activity 72
Vitamin C, intake and anti-inflammatory activity 71
Vitamin E, intake and anti-inflammatory activity 71, 78
Zinc
deficiency in inflammatory bowel disease 184
metabolic response in inflammation 65, 66